Covance Opens Fit-for-Purpose Dallas Clinical Research Unit
July 23 2015 - 8:15AM
Business Wire
LabCorp patient service center to be co-located
in new facility to serve local patients and enhance volunteer
recruitment
Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:
LH) announced today that Covance Drug Development has relocated its
clinical research unit (CRU) in Dallas, TX, to a new,
fit-for-purpose clinical research facility. The new unit, which
opened earlier this month, has expanded from 72 to 100 medical beds
and is located in the same building as the prior unit. In addition,
a LabCorp patient service center will be co-located in the CRU, at
which patients will have an opportunity to learn more about
volunteering and participating in early stage clinical trials.
“Our new Dallas facility combines advanced medical care with
numerous volunteer-friendly amenities,” said Dr. Herman Scholtz,
Vice President & General Manager, Early Clinical Services. “We
have invested in a highly customized facility designed to
facilitate the safety and quality of our studies and to enhance our
clients’ and volunteers’ experience. In addition, we are excited
about the unique opportunity to educate patients about our clinical
trials and complement our local patient recruitment capabilities
through the future LabCorp patient service center. This innovative
combination of resources is another illustration of the strategic
and operational synergies that LabCorp and Covance are gaining
through our combination.”
With more than 55,000 square feet of space, the new CRU includes
a cGMP pharmacy, dedicated ophthalmology procedure rooms, an
advanced telemetry system, and a glucose clamp suite, as well as
dedicated screening and outpatient visit areas. The pharmacy
includes three sterile and two non-sterile manufacturing suites,
which allows the site to meet current Good Manufacturing Practices.
The telemetry system enables the team to perform continuous,
high-quality data monitoring, supporting improved monitoring of
study participants and quick adjustments to treatment regimens,
when necessary.
The Dallas clinic employs approximately 75 medical and
professional staff with plans to expand to 120 employees.
In addition to the Dallas clinic, Covance offers early stage
clinical testing at three other sites in the United States and one
site in Leeds, UK. To learn more about clinical research solutions
at Covance, please visit our website at www.covance.com.
About LabCorp®
Laboratory Corporation of America® Holdings, an S&P 500
company, is the world’s leading healthcare diagnostics company,
providing comprehensive clinical laboratory services through
LabCorp Diagnostics, and end-to-end drug development support
through Covance Drug Development. LabCorp is a pioneer in
commercializing new diagnostic technologies and is improving
people’s health by delivering the combination of world-class
diagnostics, drug development and knowledge services. With combined
revenue pro forma for the acquisition of Covance in excess of $8.5
billion in 2014 and more than 48,000 employees in over 60
countries, LabCorp offers innovative solutions to healthcare
stakeholders. LabCorp clients include physicians, patients and
consumers, biopharmaceutical companies, government agencies,
managed care organizations, hospitals, and clinical labs. To learn
more about Covance Drug Development, visit www.covance.com. To
learn more about LabCorp and LabCorp Diagnostics, visit
www.labcorp.com.
This press release contains forward-looking statements including
with respect to estimated 2015 guidance and the impact of various
factors on operating results. Each of the forward-looking
statements is subject to change based on various important factors,
including without limitation, competitive actions in the
marketplace, adverse actions of governmental and other third-party
payers and the results from the Company’s acquisition of Covance.
Actual results could differ materially from those suggested by
these forward-looking statements. Further information on potential
factors that could affect LabCorp’s operating and financial results
is included in the Company’s Form 10-K for the year ended December
31, 2014, and the Company’s Form 10-Q for the quarter ended March
31, 2015, including in each case under the heading risk factors,
and in the Company’s other filings with the SEC, as well as in the
risk factors included in Covance’s filings with the SEC. The
information in this press release should be read in conjunction
with a review of the Company’s filings with the SEC including the
information in the Company’s Form 10-K for the year ended December
31, 2014, and subsequent Forms 10-Q, under the heading MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150723005194/en/
Laboratory Corporation of America® HoldingsInvestor/Media
Contact:Paul Surdez, 336-436-5076Company Information:
www.labcorp.com
Labcorp (NYSE:LH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Labcorp (NYSE:LH)
Historical Stock Chart
From Sep 2023 to Sep 2024